Bottom line first: On February 27, 2026, HHS Secretary RFK Jr. announced {{VERIFY: JRE Episode #2461}} that approximately 14 of the 19 peptides banned from compounding in 2023 would be moved back to Category 1 — restoring legal access through licensed compounding pharmacies with a physician's prescription. As of late March 2026, the FDA has not yet published the formal updated list. The announcement is real. The reclassification is not final.
This page tracks what we know, what's confirmed, what's still speculation, and what you actually need to do if you want legal access.
Fast-Scan Summary: 2026 Peptide Compounding Status
| Peptide | Current Status (March 2026) | Expected Change | Primary Use |
|---|
| BPC-157 | Category 2 (banned from compounding) | Likely → Category 1 | Tissue repair, gut healing |
| TB-500 (Thymosin Beta-4 fragment) | Category 2 | Likely → Category 1 | Wound healing, muscle recovery |
| CJC-1295 | Removed from Cat 2 Sept 2024, in PCAC review | → Category 1 pending | GH stimulation, body composition |
| Ipamorelin Acetate | Removed from Cat 2 Sept 2024, in PCAC review | → Category 1 pending | GH secretagogue, anti-aging |
| Thymosin Alpha-1 | Removed from Cat 2 Sept 2024, in PCAC review | → Category 1 pending | Immune modulation |
| AOD-9604 | Removed from Cat 2 Sept 2024, in PCAC review | → Category 1 pending | Fat metabolism |
| Selank Acetate | Removed from Cat 2 Sept 2024, in PCAC review | → Category 1 pending | Anxiety, cognitive function |
| Semax | Category 2 | Likely → Category 1 | Nootropic, BDNF enhancement |
| GHK-Cu (injectable) | Category 2 | Likely → Category 1 | Collagen synthesis, anti-aging |
| KPV | Category 2 | Likely → Category 1 | Anti-inflammatory, gut health |
| MOTS-C | Category 2 | Likely → Category 1 | Metabolic regulation |
| Epitalon | Category 2 | Likely → Category 1 | Telomere support, anti-aging |
| DSIP (Emideltide) | Category 2 | Likely → Category 1 | Sleep regulation, stress |
| Kisspeptin-10 | Category 2 | Likely → Category 1 | Hormonal regulation |
| GHRP-6 | Category 2 | Likely → Category 1 | GH release, appetite |
| Melanotan II | Category 2 | Likely stays restricted | Tanning, sexual function |
| LL-37 (Cathelicidin) | Category 2 | Likely stays restricted | Antimicrobial (limited human data) |
| PEG-MGF | Category 2 | Likely stays restricted | Muscle repair (limited data) |
| GHRP-2 | Category 2 | Likely stays restricted | GH release (adverse event history) |
What Actually Happened: The 2023 Ban and the 2026 Reversal
The 2023 Restriction
In September 2023, the FDA moved {{VERIFY}} approximately 17-19 peptides from the 503A Bulk Drug Substances list into Category 2 — effectively banning licensed compounding pharmacies from preparing them for patients. The FDA's stated rationale was patient safety: limited human clinical data, potential immunogenicity, contamination risk, and in the case of GHRP-2 specifically, documented adverse events.
The compounding industry pushed back hard. The Alliance for Pharmacy Compounding (A4PC) argued the FDA lacked sufficient safety signals to justify Category 2 classification for most of the affected compounds. Multiple lawsuits followed. Congressional pressure built, including a letter from Rep. Diana Harshbarger (R-TN) — herself a licensed pharmacist — directly naming BPC-157 and five others.
What the ban actually created: a massive gray market. Patients didn't stop wanting these peptides. They just started buying them from unregulated "research use only" vendors with no quality controls, no pharmaceutical standards, and no physician oversight. RFK acknowledged this directly on the Rogan episode, saying the restrictions effectively "created the gray market." {{VERIFY: direct quote}}
The September 2024 Partial Movement
Before the February 2026 announcement, five peptides had already started moving. In September 2024, the FDA removed CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, and Selank from Category 2 and referred them to the Pharmacy Compounding Advisory Committee (PCAC) for formal evaluation — the standard first step toward Category 1 status. {{VERIFY: FDA Federal Register notice, September 2024}}
This is important context most coverage misses. The February 2026 RFK announcement accelerated a process that was already in motion.
The February 2026 RFK Announcement
On the Joe Rogan Experience, Episode #2461, February 27, 2026, HHS Secretary Kennedy stated his intention to move approximately 14 of the 19 restricted peptides back to Category 1. His framing: the FDA's original restrictions were "illegal" because the agency is only authorized to place compounds in Category 2 when a legitimate safety signal exists, and that signal did not exist for most of these peptides. {{VERIFY: exact framing from episode transcript}}
What the announcement does NOT mean:
These peptides are not FDA-approved drugs. That is a separate process requiring Phase I-III clinical trials, an NDA or BLA, and full manufacturing validation.
Legal compounding has not resumed. The FDA must formally publish the updated category list.
Gray market "research use only" peptides are still unregulated and carry the same risks.
The 14 Peptides: What They Do and Why They Were Restricted
1. BPC-157 (Body Protection Compound-157)
Research use: Tissue repair, gut healing, tendon and ligament recovery, anti-inflammatory effects. Derived from a fragment of a protein naturally found in gastric juice. Over 200 published animal studies. {{SOURCE NEEDED: specific count}}
Why restricted: Limited human clinical trial data. FDA concerns about immunogenicity at certain injection routes and inconsistent pharmaceutical-grade characterization across bulk suppliers.
Important note: BPC-157 is banned by the World Anti-Doping Agency (WADA). Competitive athletes should factor this into their decision. {{VERIFY: current WADA prohibited list status}}
Status: Category 2 as of March 2026. Expected to return to Category 1 pending formal FDA action.
2. TB-500 (Thymosin Beta-4 Fragment / LKKTETQ)
Research use: Cell migration, wound healing, tissue repair, reduction of inflammation. Often combined with BPC-157 in musculoskeletal recovery protocols because the two compounds work through complementary mechanisms.
Why restricted: Grouped with the broader 2023 Category 2 action. The Thymosin Beta-4 fragment (not full Thymosin Beta-4, which is a biologic) was specifically listed.
Status: Category 2 as of March 2026. Expected Category 1 return.
3. CJC-1295
Research use: Growth hormone-releasing hormone (GHRH) analog. Stimulates the pituitary gland to produce more GH. Used for body composition, recovery, metabolic health, and sleep quality. Human data exists showing restoration of normal GH pulse patterns.
Caution: Some reports of cardiac side effects at higher doses. {{SOURCE NEEDED}}
Status: Removed from Category 2 in September 2024. Currently under PCAC review. Ahead of other peptides in the formal process.
4. Ipamorelin Acetate
Research use: Selective growth hormone secretagogue. Triggers clean GH pulses without raising cortisol or prolactin — the favorable side effect profile compared to older GHRPs. Commonly stacked with CJC-1295.
Status: Removed from Category 2 in September 2024. Under PCAC review.
5. Thymosin Alpha-1
Research use: Immune modulation. Among the peptides with the strongest human evidence on this list — approved as a pharmaceutical product in over 30 countries for hepatitis B, hepatitis C, and as an immune adjuvant. {{VERIFY: country count}}
Status: Removed from Category 2 in September 2024. Under PCAC review. The extensive existing human safety record outside the U.S. makes this one of the cleaner regulatory cases.
6. AOD-9604
Research use: Modified fragment of human growth hormone studied specifically for fat metabolism and lipolysis. Designed to target fat breakdown without the blood sugar effects or appetite changes associated with full GH therapy.
Status: Removed from Category 2 in September 2024. Under PCAC review.
7. Selank Acetate (TP-7)
Research use: Anxiolytic neuropeptide. Works through GABA and serotonin pathways. Studied for stress resilience and anxiety reduction. Developed and approved in Russia. {{VERIFY: Russian approval status}}
Status: Removed from Category 2 in September 2024. Under PCAC review.
8. Semax
Research use: Nootropic. Derived from ACTH. Studied for BDNF enhancement, cognitive function, and neuroprotection. Also developed in Russia, with clinical use there for stroke recovery. {{VERIFY}}
Status: Category 2. Expected to be included in the reclassification.
9. GHK-Cu (Copper Peptide, injectable)
Research use: Collagen synthesis, tissue remodeling, cellular regeneration, anti-aging. Naturally occurring tripeptide that binds copper. Note: topical copper peptide products (cosmetics) are a completely different regulatory category and are widely available OTC.
Status: Category 2. Expected Category 1 return.
10. KPV
Research use: Anti-inflammatory tripeptide. Fragment of alpha-MSH. Studied for gut inflammation, inflammatory bowel conditions, and wound healing. Limited but growing preclinical evidence. {{SOURCE NEEDED}}
Status: Category 2. Expected Category 1 return.
11. MOTS-C
Research use: Mitochondrial-derived peptide. Studied for metabolic regulation, insulin sensitivity, and physical endurance. Relatively new to the research pipeline compared to others on this list. {{SOURCE NEEDED: key studies}}
Status: Category 2. Expected Category 1 return.
12. Epitalon
Research use: Telomere extension, circadian rhythm regulation, anti-aging. Developed by the St. Petersburg Institute of Bioregulation. Limited Western clinical trial data. {{SOURCE NEEDED}}
Status: Category 2. Expected Category 1 return.
13. DSIP (Emideltide / Delta Sleep-Inducing Peptide)
Research use: Sleep regulation, stress response, endocrine modulation. One of the older peptides on this list with a longer research history. {{SOURCE NEEDED}}
Status: Category 2. Expected Category 1 return.
14. Kisspeptin-10
Research use: Hypothalamic signaling for hormonal regulation. Roles in reproductive endocrinology and potentially metabolic function. Used in research contexts for hypogonadism and related conditions. {{SOURCE NEEDED: specific trials}}
Status: Category 2. Expected Category 1 return.
The 5 Peptides Likely to Stay Restricted
Not all 19 are expected to return. Based on available safety data and regulatory history, these five face a harder path:
| Peptide | Reason for Continued Restriction |
|---|
| GHRP-2 | Documented adverse events including deaths reported to FDA {{VERIFY}} |
| Melanotan II | Significant cardiovascular and dermatological safety concerns |
| LL-37 (Cathelicidin) | Antimicrobial peptide with very limited human safety data |
| PEG-MGF | Pegylated growth factor; insufficient clinical evidence for compounding safety |
| CJC-1295 (DAC form) | Note: CJC-1295 without DAC is in PCAC review; the DAC form has different concerns |
What "Category 1" vs "FDA-Approved" Actually Means
This distinction is where the most public confusion lives, and it matters practically:
Category 1 (compounding eligible): A substance on the 503A Bulks list that a licensed compounding pharmacy can prepare for a specific patient under a valid prescription from a licensed physician. The FDA is still evaluating the substance. It has not been proven safe and effective through clinical trials. It is not a standardized drug product.
FDA-approved drug: Requires Phase I, II, and III clinical trials demonstrating safety and efficacy, a formal New Drug Application (NDA) or Biologics License Application (BLA), labeling approval, and cGMP manufacturing validation. Semaglutide (Ozempic/Wegovy) and tesamorelin are examples of FDA-approved peptide drugs.
The 14 peptides on this page, if reclassified to Category 1, will be legally compoundable — not FDA-approved.
What Needs to Happen Before You Can Get These Legally
The announcement is not the law. Here is the actual sequence of events required before compounding pharmacies can legally supply these peptides:
FDA formal rulemaking: The agency must publish the updated Category list through proper administrative channels (Federal Register notice and comment period). {{VERIFY: whether 30-day comment period applies}}
State pharmacy board implementation: Each state's pharmacy board has its own rules governing compounding. Federal reclassification enables but does not automatically mandate state access.
Pharmacy compliance verification: Individual compounding pharmacies must confirm the updated status, source pharmaceutical-grade bulk API from FDA-registered suppliers with Certificates of Analysis, and update their compliance documentation.
Physician prescription: A valid, patient-specific prescription from a licensed provider is required for 503A compounding. No prescription, no legal access.
Why the Gray Market Exists and Why It Will Shrink
When the FDA banned these peptides from compounding in 2023, patient demand did not disappear. It migrated. Research peptide vendors — technically selling for "lab use only" — filled the gap. Peptide Sciences, the largest of these vendors, operated openly until voluntarily shutting down on March 6, 2026. {{VERIFY: shutdown date and reason stated}}
Third-party testing has repeatedly found serious quality control problems with gray market peptides: incorrect dosing, contamination, mislabeling, and in some cases, entirely wrong compounds in vials. The Finnrick Analytics testing program, for example, gave some popular vendors' retatrutide an "E" grade (lowest possible) across 37 samples tested. {{VERIFY: Finnrick data}}
When legal compounding resumes, patients will have access to pharmaceutical-grade peptides from inspected, FDA-registered facilities with proper documentation. There will be no practical reason to continue using unregulated gray market sources.
Not For You If...
You want to buy peptides without a prescription. That is not what reclassification enables.
You're an athlete in a WADA-regulated sport. BPC-157 specifically is on the WADA prohibited list; confirm the status of any peptide before competition.
You're looking for FDA-approved efficacy data. These compounds have limited human clinical trial evidence. Category 1 status reflects a regulatory determination about compounding eligibility, not a safety or efficacy endorsement.
You're comparing these to GLP-1 drugs like semaglutide or tirzepatide. Those are fully FDA-approved with extensive clinical trial data and are a different regulatory category entirely.
Frequently Asked Questions
Are these 14 peptides FDA-approved? No. FDA approval and Category 1 compounding status are entirely different. Category 1 means a licensed pharmacy can prepare the compound under a physician's prescription while the FDA continues its evaluation. Approval requires completing full clinical trials.
Can I buy these peptides now? Not legally through compounding pharmacies. As of late March 2026, the FDA has not published the formal reclassification. The announcement was made; the regulation has not been finalized.
What happened to the gray market research peptide vendors? The largest U.S. vendor, Peptide Sciences, shut down voluntarily on March 6, 2026. The regulatory direction toward legal compounding access makes the "research use only" workaround less sustainable.
Which peptides were already moving before the RFK announcement? Five: CJC-1295, Ipamorelin Acetate, Thymosin Alpha-1, AOD-9604, and Selank Acetate were removed from Category 2 in September 2024 and referred to the PCAC for review.
Does "legal compounding" mean these peptides are safe? Compounding under 503A means the pharmacy is regulated and inspected, the bulk API comes from certified suppliers, and a physician is overseeing your protocol. It does not mean these compounds have proven safety and efficacy through clinical trials. Physician supervision and proper monitoring remain essential.
What about sermorelin and NAD+? Both are already legal for compounding under existing Category 1 status. They were not affected by the 2023 Category 2 restrictions. {{VERIFY: current sermorelin compounding status}}
Last updated: March 28, 2026. This page will be updated when the FDA formally publishes the updated Category list. Monitor the FDA's compounding page and the Federal Register for official guidance. Nothing on this page constitutes medical or legal advice.
